Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes
Sulfonylureas (SUs) may impair outcome in patients with acute coronary syndrome. Most experimental studies of the myocardial effects of SU treatment are performed in non-diabetic models. We compared the effect of two widely used SUs, glibenclamide (gb) and gliclazide (gc), with high and low myocardi...
Gespeichert in:
| Veröffentlicht in: | Diabetologia 2011-02, Vol.54 (2), p.451 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 451 |
| container_title | Diabetologia |
| container_volume | 54 |
| creator | Kristiansen, S B Løfgren, B Nielsen, J M Støttrup, N B Buhl, E S Nielsen-Kudsk, J E Nielsen, T T Rungby, J Flyvbjerg, A Bøtker, H E |
| description | Sulfonylureas (SUs) may impair outcome in patients with acute coronary syndrome. Most experimental studies of the myocardial effects of SU treatment are performed in non-diabetic models. We compared the effect of two widely used SUs, glibenclamide (gb) and gliclazide (gc), with high and low myocardial K(ATP) channel affinity, respectively, at therapeutic concentrations on infarct size, left ventricular (LV) function and myocardial glycogen, lactate and alanine content before and after ischaemia/reperfusion (I/R).
Non-diabetic Wistar and diabetic Goto-Kakizaki rat hearts were investigated in a Langendorff preparation. Gb (0.1 μmol/l) and gc (1.0 μmol/l) were administrated throughout the study. Infarct size was evaluated after 120 min of reperfusion. Myocardial metabolite content was measured before and after ischaemia.
Infarct size was smaller in diabetic hearts than in non-diabetic hearts (0.33 ± 0.03 vs 0.51 ± 0.05, p < 0.05). Gb increased infarct size (0.54 ± 0.04 vs 0.33 ± 0.03, p < 0.05) and reduced post-ischaemic LV developed pressure (60 ± 3 vs 76 ± 3 mmHg, p < 0.05) and coronary flow (4.9 ± 0.5 vs 7.1 ± 0.4 ml min(-1) g(-1), p < 0.05) in gb-treated diabetic rats compared with untreated diabetic rats. On comparing gb-treated diabetic rats with untreated diabetic rats, glycogen content was reduced before (9.1 ± 0.6 vs 13.6 ± 1.0 nmol/mg wet weight, p < 0.01) and after ischaemia (0.9 ± 0.2 vs 1.8 ± 0.2 nmol/mg wet weight, p < 0.05), and lactate (4.8 ± 0.4 vs 3.2 ± 0.3 nmol/mg wet weight, p < 0.01) and alanine (1.38 ± 0.12 vs 0.96 ± 0.09 nmol/mg wet weight, p < 0.05) contents were increased during reperfusion. Gc-treatment of diabetic and non-diabetic rats did not affect any of the measured variables.
Gb, but not gc, exacerbates I/R injury and deteriorates LV function in diabetic hearts. These effects of gb on diabetic hearts may be due to detrimental effects on myocardial carbohydrate metabolism. |
| doi_str_mv | 10.1007/s00125-010-1970-y |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_21104069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21104069</sourcerecordid><originalsourceid>FETCH-LOGICAL-p559-e027c1ce30c2ee587a4682483f1e33b485fdfee77dc4aa0edb83eb1741fb9b7f3</originalsourceid><addsrcrecordid>eNpNkMtOwzAURC0kRMvjA9igu4RF4PqROllWFS9RCRbdV3ZyTYySOIpTVeFr-FTCS2I1i5k5Gg1j5xyvOaK-iYhcpAlyTHiuMRkP2JwrKRJUIpux4xjfEFGmanHEZoJzVLjI5-xjFZrO9D6GFoKDYR8g7moX2rHe9WQi7P1QQeVfKzBtCXXYQzOGwvSlNzU8XS43L1dQVKZtqQbjnG_9MMIE-5fyrTN9MUD07_RNaWgwNtQ-NpMHBnozQBPKifA1YewIBExNSwPFU3boTB3p7FdP2ObudrN6SNbP94-r5Trp0jRPCIUueEESC0GUZtqoRSZUJh0nKa3KUlc6Iq3LQhmDVNpMkuVacWdzq508YRc_2G5nGyq3Xe8b04_bv6fkJzySbLk</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kristiansen, S B ; Løfgren, B ; Nielsen, J M ; Støttrup, N B ; Buhl, E S ; Nielsen-Kudsk, J E ; Nielsen, T T ; Rungby, J ; Flyvbjerg, A ; Bøtker, H E</creator><creatorcontrib>Kristiansen, S B ; Løfgren, B ; Nielsen, J M ; Støttrup, N B ; Buhl, E S ; Nielsen-Kudsk, J E ; Nielsen, T T ; Rungby, J ; Flyvbjerg, A ; Bøtker, H E</creatorcontrib><description><![CDATA[Sulfonylureas (SUs) may impair outcome in patients with acute coronary syndrome. Most experimental studies of the myocardial effects of SU treatment are performed in non-diabetic models. We compared the effect of two widely used SUs, glibenclamide (gb) and gliclazide (gc), with high and low myocardial K(ATP) channel affinity, respectively, at therapeutic concentrations on infarct size, left ventricular (LV) function and myocardial glycogen, lactate and alanine content before and after ischaemia/reperfusion (I/R).
Non-diabetic Wistar and diabetic Goto-Kakizaki rat hearts were investigated in a Langendorff preparation. Gb (0.1 μmol/l) and gc (1.0 μmol/l) were administrated throughout the study. Infarct size was evaluated after 120 min of reperfusion. Myocardial metabolite content was measured before and after ischaemia.
Infarct size was smaller in diabetic hearts than in non-diabetic hearts (0.33 ± 0.03 vs 0.51 ± 0.05, p < 0.05). Gb increased infarct size (0.54 ± 0.04 vs 0.33 ± 0.03, p < 0.05) and reduced post-ischaemic LV developed pressure (60 ± 3 vs 76 ± 3 mmHg, p < 0.05) and coronary flow (4.9 ± 0.5 vs 7.1 ± 0.4 ml min(-1) g(-1), p < 0.05) in gb-treated diabetic rats compared with untreated diabetic rats. On comparing gb-treated diabetic rats with untreated diabetic rats, glycogen content was reduced before (9.1 ± 0.6 vs 13.6 ± 1.0 nmol/mg wet weight, p < 0.01) and after ischaemia (0.9 ± 0.2 vs 1.8 ± 0.2 nmol/mg wet weight, p < 0.05), and lactate (4.8 ± 0.4 vs 3.2 ± 0.3 nmol/mg wet weight, p < 0.01) and alanine (1.38 ± 0.12 vs 0.96 ± 0.09 nmol/mg wet weight, p < 0.05) contents were increased during reperfusion. Gc-treatment of diabetic and non-diabetic rats did not affect any of the measured variables.
Gb, but not gc, exacerbates I/R injury and deteriorates LV function in diabetic hearts. These effects of gb on diabetic hearts may be due to detrimental effects on myocardial carbohydrate metabolism.]]></description><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-010-1970-y</identifier><identifier>PMID: 21104069</identifier><language>eng</language><publisher>Germany</publisher><subject>Animals ; Diabetes Mellitus, Type 2 - drug therapy ; Gliclazide - adverse effects ; Gliclazide - therapeutic use ; Glyburide - adverse effects ; Glyburide - therapeutic use ; Glycogen - metabolism ; Lactic Acid - metabolism ; Male ; Myocardial Infarction - chemically induced ; Myocardial Infarction - metabolism ; Myocardium - metabolism ; Potassium Channels - drug effects ; Rats ; Rats, Wistar ; Sulfonylurea Compounds - adverse effects ; Sulfonylurea Compounds - therapeutic use</subject><ispartof>Diabetologia, 2011-02, Vol.54 (2), p.451</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21104069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kristiansen, S B</creatorcontrib><creatorcontrib>Løfgren, B</creatorcontrib><creatorcontrib>Nielsen, J M</creatorcontrib><creatorcontrib>Støttrup, N B</creatorcontrib><creatorcontrib>Buhl, E S</creatorcontrib><creatorcontrib>Nielsen-Kudsk, J E</creatorcontrib><creatorcontrib>Nielsen, T T</creatorcontrib><creatorcontrib>Rungby, J</creatorcontrib><creatorcontrib>Flyvbjerg, A</creatorcontrib><creatorcontrib>Bøtker, H E</creatorcontrib><title>Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><description><![CDATA[Sulfonylureas (SUs) may impair outcome in patients with acute coronary syndrome. Most experimental studies of the myocardial effects of SU treatment are performed in non-diabetic models. We compared the effect of two widely used SUs, glibenclamide (gb) and gliclazide (gc), with high and low myocardial K(ATP) channel affinity, respectively, at therapeutic concentrations on infarct size, left ventricular (LV) function and myocardial glycogen, lactate and alanine content before and after ischaemia/reperfusion (I/R).
Non-diabetic Wistar and diabetic Goto-Kakizaki rat hearts were investigated in a Langendorff preparation. Gb (0.1 μmol/l) and gc (1.0 μmol/l) were administrated throughout the study. Infarct size was evaluated after 120 min of reperfusion. Myocardial metabolite content was measured before and after ischaemia.
Infarct size was smaller in diabetic hearts than in non-diabetic hearts (0.33 ± 0.03 vs 0.51 ± 0.05, p < 0.05). Gb increased infarct size (0.54 ± 0.04 vs 0.33 ± 0.03, p < 0.05) and reduced post-ischaemic LV developed pressure (60 ± 3 vs 76 ± 3 mmHg, p < 0.05) and coronary flow (4.9 ± 0.5 vs 7.1 ± 0.4 ml min(-1) g(-1), p < 0.05) in gb-treated diabetic rats compared with untreated diabetic rats. On comparing gb-treated diabetic rats with untreated diabetic rats, glycogen content was reduced before (9.1 ± 0.6 vs 13.6 ± 1.0 nmol/mg wet weight, p < 0.01) and after ischaemia (0.9 ± 0.2 vs 1.8 ± 0.2 nmol/mg wet weight, p < 0.05), and lactate (4.8 ± 0.4 vs 3.2 ± 0.3 nmol/mg wet weight, p < 0.01) and alanine (1.38 ± 0.12 vs 0.96 ± 0.09 nmol/mg wet weight, p < 0.05) contents were increased during reperfusion. Gc-treatment of diabetic and non-diabetic rats did not affect any of the measured variables.
Gb, but not gc, exacerbates I/R injury and deteriorates LV function in diabetic hearts. These effects of gb on diabetic hearts may be due to detrimental effects on myocardial carbohydrate metabolism.]]></description><subject>Animals</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Gliclazide - adverse effects</subject><subject>Gliclazide - therapeutic use</subject><subject>Glyburide - adverse effects</subject><subject>Glyburide - therapeutic use</subject><subject>Glycogen - metabolism</subject><subject>Lactic Acid - metabolism</subject><subject>Male</subject><subject>Myocardial Infarction - chemically induced</subject><subject>Myocardial Infarction - metabolism</subject><subject>Myocardium - metabolism</subject><subject>Potassium Channels - drug effects</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Sulfonylurea Compounds - adverse effects</subject><subject>Sulfonylurea Compounds - therapeutic use</subject><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMtOwzAURC0kRMvjA9igu4RF4PqROllWFS9RCRbdV3ZyTYySOIpTVeFr-FTCS2I1i5k5Gg1j5xyvOaK-iYhcpAlyTHiuMRkP2JwrKRJUIpux4xjfEFGmanHEZoJzVLjI5-xjFZrO9D6GFoKDYR8g7moX2rHe9WQi7P1QQeVfKzBtCXXYQzOGwvSlNzU8XS43L1dQVKZtqQbjnG_9MMIE-5fyrTN9MUD07_RNaWgwNtQ-NpMHBnozQBPKifA1YewIBExNSwPFU3boTB3p7FdP2ObudrN6SNbP94-r5Trp0jRPCIUueEESC0GUZtqoRSZUJh0nKa3KUlc6Iq3LQhmDVNpMkuVacWdzq508YRc_2G5nGyq3Xe8b04_bv6fkJzySbLk</recordid><startdate>201102</startdate><enddate>201102</enddate><creator>Kristiansen, S B</creator><creator>Løfgren, B</creator><creator>Nielsen, J M</creator><creator>Støttrup, N B</creator><creator>Buhl, E S</creator><creator>Nielsen-Kudsk, J E</creator><creator>Nielsen, T T</creator><creator>Rungby, J</creator><creator>Flyvbjerg, A</creator><creator>Bøtker, H E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201102</creationdate><title>Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes</title><author>Kristiansen, S B ; Løfgren, B ; Nielsen, J M ; Støttrup, N B ; Buhl, E S ; Nielsen-Kudsk, J E ; Nielsen, T T ; Rungby, J ; Flyvbjerg, A ; Bøtker, H E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p559-e027c1ce30c2ee587a4682483f1e33b485fdfee77dc4aa0edb83eb1741fb9b7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Gliclazide - adverse effects</topic><topic>Gliclazide - therapeutic use</topic><topic>Glyburide - adverse effects</topic><topic>Glyburide - therapeutic use</topic><topic>Glycogen - metabolism</topic><topic>Lactic Acid - metabolism</topic><topic>Male</topic><topic>Myocardial Infarction - chemically induced</topic><topic>Myocardial Infarction - metabolism</topic><topic>Myocardium - metabolism</topic><topic>Potassium Channels - drug effects</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Sulfonylurea Compounds - adverse effects</topic><topic>Sulfonylurea Compounds - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kristiansen, S B</creatorcontrib><creatorcontrib>Løfgren, B</creatorcontrib><creatorcontrib>Nielsen, J M</creatorcontrib><creatorcontrib>Støttrup, N B</creatorcontrib><creatorcontrib>Buhl, E S</creatorcontrib><creatorcontrib>Nielsen-Kudsk, J E</creatorcontrib><creatorcontrib>Nielsen, T T</creatorcontrib><creatorcontrib>Rungby, J</creatorcontrib><creatorcontrib>Flyvbjerg, A</creatorcontrib><creatorcontrib>Bøtker, H E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kristiansen, S B</au><au>Løfgren, B</au><au>Nielsen, J M</au><au>Støttrup, N B</au><au>Buhl, E S</au><au>Nielsen-Kudsk, J E</au><au>Nielsen, T T</au><au>Rungby, J</au><au>Flyvbjerg, A</au><au>Bøtker, H E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes</atitle><jtitle>Diabetologia</jtitle><addtitle>Diabetologia</addtitle><date>2011-02</date><risdate>2011</risdate><volume>54</volume><issue>2</issue><spage>451</spage><pages>451-</pages><eissn>1432-0428</eissn><abstract><![CDATA[Sulfonylureas (SUs) may impair outcome in patients with acute coronary syndrome. Most experimental studies of the myocardial effects of SU treatment are performed in non-diabetic models. We compared the effect of two widely used SUs, glibenclamide (gb) and gliclazide (gc), with high and low myocardial K(ATP) channel affinity, respectively, at therapeutic concentrations on infarct size, left ventricular (LV) function and myocardial glycogen, lactate and alanine content before and after ischaemia/reperfusion (I/R).
Non-diabetic Wistar and diabetic Goto-Kakizaki rat hearts were investigated in a Langendorff preparation. Gb (0.1 μmol/l) and gc (1.0 μmol/l) were administrated throughout the study. Infarct size was evaluated after 120 min of reperfusion. Myocardial metabolite content was measured before and after ischaemia.
Infarct size was smaller in diabetic hearts than in non-diabetic hearts (0.33 ± 0.03 vs 0.51 ± 0.05, p < 0.05). Gb increased infarct size (0.54 ± 0.04 vs 0.33 ± 0.03, p < 0.05) and reduced post-ischaemic LV developed pressure (60 ± 3 vs 76 ± 3 mmHg, p < 0.05) and coronary flow (4.9 ± 0.5 vs 7.1 ± 0.4 ml min(-1) g(-1), p < 0.05) in gb-treated diabetic rats compared with untreated diabetic rats. On comparing gb-treated diabetic rats with untreated diabetic rats, glycogen content was reduced before (9.1 ± 0.6 vs 13.6 ± 1.0 nmol/mg wet weight, p < 0.01) and after ischaemia (0.9 ± 0.2 vs 1.8 ± 0.2 nmol/mg wet weight, p < 0.05), and lactate (4.8 ± 0.4 vs 3.2 ± 0.3 nmol/mg wet weight, p < 0.01) and alanine (1.38 ± 0.12 vs 0.96 ± 0.09 nmol/mg wet weight, p < 0.05) contents were increased during reperfusion. Gc-treatment of diabetic and non-diabetic rats did not affect any of the measured variables.
Gb, but not gc, exacerbates I/R injury and deteriorates LV function in diabetic hearts. These effects of gb on diabetic hearts may be due to detrimental effects on myocardial carbohydrate metabolism.]]></abstract><cop>Germany</cop><pmid>21104069</pmid><doi>10.1007/s00125-010-1970-y</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1432-0428 |
| ispartof | Diabetologia, 2011-02, Vol.54 (2), p.451 |
| issn | 1432-0428 |
| language | eng |
| recordid | cdi_pubmed_primary_21104069 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Diabetes Mellitus, Type 2 - drug therapy Gliclazide - adverse effects Gliclazide - therapeutic use Glyburide - adverse effects Glyburide - therapeutic use Glycogen - metabolism Lactic Acid - metabolism Male Myocardial Infarction - chemically induced Myocardial Infarction - metabolism Myocardium - metabolism Potassium Channels - drug effects Rats Rats, Wistar Sulfonylurea Compounds - adverse effects Sulfonylurea Compounds - therapeutic use |
| title | Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T16%3A38%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20two%20sulfonylureas%20with%20high%20and%20low%20myocardial%20K(ATP)%20channel%20affinity%20on%20myocardial%20infarct%20size%20and%20metabolism%20in%20a%20rat%20model%20of%20type%202%20diabetes&rft.jtitle=Diabetologia&rft.au=Kristiansen,%20S%20B&rft.date=2011-02&rft.volume=54&rft.issue=2&rft.spage=451&rft.pages=451-&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-010-1970-y&rft_dat=%3Cpubmed%3E21104069%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21104069&rfr_iscdi=true |